Pacer Advisors Inc. Has $1.37 Million Position in Repligen Corporation $RGEN

Pacer Advisors Inc. boosted its position in shares of Repligen Corporation (NASDAQ:RGEN) by 305.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,213 shares of the biotechnology company’s stock after buying an additional 7,694 shares during the quarter. Pacer Advisors Inc.’s holdings in Repligen were worth $1,365,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its position in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the last quarter. Center for Financial Planning Inc. increased its position in Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 126 shares during the period. Trust Co. of Vermont bought a new stake in Repligen during the 3rd quarter worth about $67,000. AlphaQuest LLC acquired a new position in Repligen during the 2nd quarter valued at about $104,000. Finally, Hilltop National Bank acquired a new position in Repligen during the 2nd quarter valued at about $147,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Barclays lifted their price target on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group upped their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. HSBC began coverage on Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target on the stock. Hsbc Global Res raised Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Finally, Evercore ISI increased their target price on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $177.92.

Repligen Stock Performance

Shares of Repligen stock opened at $163.86 on Friday. The stock’s fifty day simple moving average is $159.12 and its 200 day simple moving average is $138.12. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $9.22 billion, a PE ratio of 8,197.10, a PEG ratio of 3.68 and a beta of 1.11. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. During the same period in the previous year, the firm earned $0.43 earnings per share. The company’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, research analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Insider Activity at Repligen

In related news, COO James Bylund sold 2,191 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 49,657 shares of company stock worth $7,721,077. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.